Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass

Bone

Volumn 26, Issue 3, 2000, Pages 269-274

  Filipponi, P ^a   Cristallini, S ^a   Policani, G ^a   Schifini, M F ^a   Casciari, C ^a   Garinei, P ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Hospital of Umbertide   (Italy)

Author keywords

Bisphosphonates; Bone turnover; Clodronate; Intermittent bisphosphonate administration; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CLODRONIC ACID; COLLAGEN TYPE 1; VITAMIN D;

ADULT; AGED; ARTICLE; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; FEMUR NECK; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; CLODRONIC ACID; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE;

EID: 0033956103     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00273-2     Document Type: Article

References (25)

1. Adami S., Zamberlan N., Mian M., Dorizzi R., Rosini S., Braga B., Gatti D., Bertoldo F., LoCascio V. Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone Miner. 25:1994;75-82.
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E. Randomised trial of effects of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1996;1535-1541.
3. Boyce B.F., Fogelman I., Ralson S., Smith L., Johnston E., Boyle I.T. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease. Lancet. i:1984;821-824.
4. Composton J.E. The therapeutic use of bisphosphonates. Br Med J. 309:1994;711-715.
5. Devogelaer J.P., Nagant de Deuxchaisnes C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate) a non-linear increase of lumbar bone mineral density . Christiansen C., Overgaard K. Osteoporosis 1990. 1990;1507-1509 Osteopress, Copenhagen.
6. Filipponi P., Pedetti M., Fedeli L., Cini L., Boldrini S., Massoni C., Cristallini S. Cyclical clodronate is effective in preventing postmenopausal bone loss a comparative study with transcutaneous hormone replacement therapy . J Bone Miner Res. 5:1995;697-703.
7. Filipponi P., Cristallini S., Rizzello E., Policani G., Fedeli L., Gregorio F., Boldrini S., Troiani S., Massoni C. Cyclical intravenous clodronate in postmenopausal osteoporosis Results of a long-term clinical trial . Bone. 18:1996;179-184.
8. Fleish H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic snd metabolic bone disease. Drugs. 42:1991;919-944.
9. Giannini S., D'Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 14:1993;137-141.
10. Giorgino R., Mancuso S. Oral alendronate and calcaneus ultrasound densitometry a three-year prospective study . Osteoporosis Int. 7:(Suppl.2):1997;15.
11. Heaney R.P. The bone-remodeling transient implications for the interpretation of clinical studies of bone mass change . J Bone Miner Res. 9:1994;1515-1523.
12. Harris S.T., Gertz B.J., Eyre D.R., Genant H.K., Survill T.T., Chestnut C.H. The effect of short-term treatment with alendronate upon vertebral density and biochemical markers of bone remodelling in early postmenopausal osteoporosis. J Clin Endocrinol Metab. 76:1993;1399-1406.
13. Heikkinen J.E., Selander K.S., Laitinen K., Arnala I., Väänänen H.K. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res. 12:1997;103-110.
14. Kanis J.A., McCloskey E.V. The use of clodronate in disorders of calcium and skeletal metabolism. Kanis J.A. Calcium Metabolism. Progress in Basic and Clinical Pharmacology. 1990;89-136 Karger, Basel.
15. Kanis, J. A. Treatment of generalized osteoporosis with inhibitors of bone resorption. In: Kanis, J. A., Ed. Textbook of Osteoporosis. London: Blackwell Science; 1996; 308, 367.
16. Minaire P., Bernard E., Meunier P.J., Edouard C., Goedert G., Pilonchery G. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest. 68:1981;1086-1092.
17. Parfitt A.M., Mundy G.R., Roodman G.D., Hughes D.E., Boyce B.F. A new model for the regulation of bone resorption with particular reference to the effects of bisphosphonates. J Bone Miner Res. 11:1996;150-159.
18. Passeri M., Baroni M.C., Pedrazzoni M., Pioli G., Barbagallo M., Costi D., Biondi M., Girasole G., Arlunno B., Palummeri E. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. 15:1991;237-248.
19. Reginster J.Y., Deroisy R., Denis D., Collette J., Lecart M.P., Sarlet N., Ethgen D., Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. ii:1989;1469-1471.
20. Rossini M., Gatti D., Zamberlan N., Braga V., Dorizzi R., Adami S. Long term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res. 9:1994;1833-1837.
21. Rossini M., Braga V., Gatti D., Gerardi D., Zamberlan N., Adami S. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 24:1999;125-129.
22. Stock J.L., Norman H.B., Chesnut C.H. III, Ensrud K.E., Genant H.K., Harris S.T., McClung M.R., Singer F.R., Yood R.A., Pryor-Tillotson S., Wei L., Santora A.C. II. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 103:1997;291-297.
23. Thiébaud D., Burkhardt P., Melchior J., Eckert P., Jacquet A.F., Scnyder P., Gobelet C. Two years' effectiveness of intavenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteporosis Int. 4:1994;76-83.
24. Thiébaud D., Burkhardt P., Kriegbaum H., Huss H., Mulder H., Juttmann J.R., Schöter K.H. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 103:1997;298-307.
25. Vasikaran S.D., Khan S., McCloskey E.V., Kanis J.A. Sustained response to intravenous alendronate in postmenopausal osteoporosis. Bone. 17:1995;517-520.